Literature DB >> 7097334

Current prognosis in overt neonatal hydrocephalus.

D C McCullough, L A Balzer-Martin.   

Abstract

Chiefly because of advances in prenatal diagnostic ultrasonography, prognostic data on congenital hydrocephalus have increased in pertinence. Neurosurgeons may be confronted with requests for prognostic information after discovery of gestational hydrocephalus. Because previous reports reflect technical problems, complications, and less favorable results of an evolutionary period in hydrocephalus therapy, the authors have attempted to update the prognostic picture with a review of their results in hydrocephalus that is overt at birth. the status of 37 children treated with cerebrospinal fluid shunts after delivery at term with overt hydrocephalus was evaluated after an average 6-year follow-up period. They represented 8% of all children being followed for hydrocephalus. Outcome was also reviewed in 11 patients with severe hydrocephalus who were not treated. Of treated patients, 86% survived 1 to 16 years, while all of the untreated infants died at an average of 2.5 months. Approximately two-thirds of treated patients have normal or borderline intellectual capabilities (mean IQ 96, standard deviation 22). Dandy-Walker malformation was associated with a high mortality and a very low IQ in survivors. Congenital aqueductal atresia was also associated with intellectual impairment, but children with communicating hydrocephalus and myelomeningocele were not intellectually impaired. Among the survivors with low IQ, the poor outcome was generally predictable on the basis of cortical mantle thickness and "brain mass" calculations before therapy. The findings from this partially selected series indicate that the majority of babies born with overt hydrocephalus have a good prognosis with appropriate therapy.

Entities:  

Mesh:

Year:  1982        PMID: 7097334     DOI: 10.3171/jns.1982.57.3.0378

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  19 in total

1.  Surgical treatment and long-term neurodevelopmental outcome for infants with idiopathic aqueductal stenosis.

Authors:  W C Hanigan; A Morgan; A Shaaban; P Bradle
Journal:  Childs Nerv Syst       Date:  1991-11       Impact factor: 1.475

2.  Months and days fly like arrows.

Authors:  K Sato
Journal:  Childs Nerv Syst       Date:  1996-08       Impact factor: 1.475

3.  Psychometric intelligence after infantile hydrocephalus. A critical review and reinterpretation.

Authors:  J Donders; A I Canady; B P Rourke
Journal:  Childs Nerv Syst       Date:  1990-05       Impact factor: 1.475

Review 4.  Neuropsychological findings in congenital and acquired childhood hydrocephalus.

Authors:  M Mataró; C Junqué; M A Poca; J Sahuquillo
Journal:  Neuropsychol Rev       Date:  2001-12       Impact factor: 7.444

5.  Diagnosis of brain neuropathology in utero.

Authors:  D H Pretorius; P D Russ; C M Rumack; M L Manco-Johnson
Journal:  Neuroradiology       Date:  1986       Impact factor: 2.804

6.  Shunt placement and myelomeningocele repair: simultaneous vs sequential shunting. Review of 12 cases.

Authors:  N E Epstein; A D Rosenthal; J Zito; M Osipoff
Journal:  Childs Nerv Syst       Date:  1985       Impact factor: 1.475

7.  Perinatal unilateral hydrocephalus. Atresia of the foramen of Monro.

Authors:  B M Gaston; B E Jones
Journal:  Pediatr Radiol       Date:  1989

8.  Prenatal diagnosis and management of fetal hydrocephaly and lissencephaly.

Authors:  W Holzgreve; R Feil; F Louwen; P Miny
Journal:  Childs Nerv Syst       Date:  1993-11       Impact factor: 1.475

9.  Intelligence outcome in children with shunted hydrocephalus of different etiology.

Authors:  D Riva; N Milani; C Giorgi; C Pantaleoni; C Zorzi; M Devoti
Journal:  Childs Nerv Syst       Date:  1994-01       Impact factor: 1.475

10.  The subcutaneous ventricular reservoir: an effective treatment for posthemorrhagic hydrocephalus.

Authors:  S J Gaskill; A E Marlin; S Rivera
Journal:  Childs Nerv Syst       Date:  1988-10       Impact factor: 1.475

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.